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Background: Abnormal ventricular repolarization is a predictor of cardiovascular mortality. In this study, we tested
the hypothesis that glycemic control reverses abnormal ventricular repolarization in patients with type 2 diabetes.
Methods: We analyzed longitudinal changes in repolarization indices of electrocardiograms in retrospectively
enrolled 44 patients with type 2 diabetes and 44 age-matched healthy subjects.
Results: In the diabetic group, BMI was greater, levels of HbA1c (10.0 ± 1.6 vs. 5.6 ± 0.3%) and triglyceride were
higher and level of HDL cholesterol was lower than those in the control group. Although mean QTc intervals were
similar (413.6 ± 18.5 vs. 408.3 ± 22.7 ms), QT dispersion (41.8 ± 15.4 vs. 28.7 ± 7.7 ms) and Tpeak-Tend in lead V5
(83.6 ± 13.6 vs. 71.3 ± 10.3 ms) were significantly longer in the diabetic group than in the control group, indicating
increased heterogeneity of ventricular repolarization in type 2 diabetes. During follow-up of 36 patients in the
diabetic group for 787 ± 301 days, HbA1c level decreased to 7.3 ± 1.6%, while BMI did not significantly change. In
contrast to HbA1c, QT dispersion (45.8 ± 15.0 ms) and Tpeak-Tend in lead V5 (83.6 ± 10.6 ms) were not significantly
reduced during the follow-up period. There was no correlation between the change in HbA1c and the change in
QT dispersion or Tpeak-Tend.
Conclusions: Increased heterogeneity of ventricular repolarization in type 2 diabetic patients was not reduced
during the relatively short follow-up period despite significantly improved glycemic control.
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The number of patients with type 2 diabetes has been
increasing worldwide in the past two decades, and these
patients are predisposed to serious cardiovascular mor-
bidity and mortality [1,2]. Despite recent progress in cor-
onary intervention strategies, diabetes is associated with
high mortality after acute myocardial infarction (MI)
due to extensive atherosclerotic lesions and also a hyper-
trophied and dysfunctional left ventricle [3]. It has been
reported that post-MI patients with diabetes have higher
incidences of heart failure, recurrent myocardial ischemic
events and sudden cardiac death (SCD) than do those
without diabetes [4]. In the UKPDS, glycemic control* Correspondence: miura@sapmed.ac.jp
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unless otherwise stated.significantly reduced the incidence of microvascular dis-
ease but had limited effects on cardiovascular events in-
cluding SCD [5]. Furthermore, recent large clinical trials
have shown that no significant reduction of major adverse
cardiac events was achieved by 2–5 years of intensive gly-
cemic control [6-10].
An electrocardiogram (ECG) is the most widely used
noninvasive diagnostic test for cardiovascular risk stratifi-
cation. It is well known that repolarization abnormalities,
such as prolonged QT interval (or heart rate-corrected
QT interval (QTc)) and increased QT dispersion, are asso-
ciated with increased risk of malignant ventricular ar-
rhythmias and SCD in high-risk populations (i.e., patients
with myocardial infarction and cardiomyopathy) [11]. Fur-
thermore, most, but not all, studies have shown that pro-
longed QTc and increased QT dispersion were predictors
of all-cause and cardiovascular mortality in the general
population [12,13] and probably in diabetic patients as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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T wave (Tpeak-Tend) is known to reflect transmural repo-
larization heterogeneity and has been associated with in-
creased risk of mortality not only in high-risk patients
[18,19] but also in the general population [20,21]. Import-
antly, Tpeak-Tend has been shown to predict cardiovascu-
lar mortality even when the QTc interval is normal [21].
However, its importance in diabetic patients has yet to be
determined. In addition, it is unclear whether blood
glucose-lowering therapy modifies the spatial heterogen-
eity in repolarization, if any, in diabetic patients. In the
present study, we tested the hypotheses that repolarization
heterogeneity is enlarged in patients with type 2 diabetes
and that glycemic control alleviates the abnormality in
repolarization.Methods
This study was conducted in strict adherence with the
principles of the Declaration of Helsinki and was ap-
proved by the Clinical Investigation Ethics Committee of
Sapporo Medical University Hospital.Figure 1 Enrollment and follow-up of study participants.Subjects
We retrospectively analyzed data for 275 consecutive pa-
tients who were admitted to our hospital for manage-
ment of type 2 diabetes from April 2007 to September
2012. Control subjects were chosen from the Tanno-
Sobetsu cohort [22], in which residents of two Japanese
rural towns, Tanno and Sobetsu, have been prospectively
followed up by annual or biannual medical examination,
including standard blood tests and ECG. We selected
age- and sex-matched healthy subjects who had not been
receiving any medications. Exclusion criteria were type 1
diabetes and other specific types of diabetes, atrial fibril-
lation, past history of cardiac surgery, chronic kidney
disease at stage 4 or higher, serum potassium abnormal-
ity (<3.5 or >5.5 mEq/l), use of an anti-arrhythmic drug
(except a β blocker used for hypertension or coronary
artery disease), bundle branch block, overt heart disease,
and low T wave amplitude at lead V5 (<0.1 mV). By the
exclusion criteria, 231 diabetic patients were excluded,
and 44 type 2 diabetic patients and 44 age- and sex-
matched non-diabetic controls were enrolled in this
study (Figure 1). Autonomic neuropathy was defined as
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with a fall in systolic blood pressure ≥20 mmHg [23,24].
After discharge from our hospital, the patients were
followed up at the outpatient clinic. We retrospectively
analyzed longitudinal changes in clinical parameters dur-
ing follow-up for 227–1374 days (i.e., follow-up until
April 2014) under glucose-lowering therapy. The medi-
cation was adjusted by each physician’s decision to
optimize the glycemic control.
Clinical characteristics, laboratory data and ECG find-
ings were compared between the type 2 diabetic group
and the control group and before and after the glycemic
control within the type 2 diabetic group.ECG recordings and measurements
Standard resting 12-lead ECGs were recorded at 25 mm/s
paper speed and 10 mm/mV amplitude. The beginning of
the QT interval was defined as first deflection of the QRS
complex. The end of the T wave was defined as the inter-
section of the tangent to the down slope of the T wave
and the isoelectric line when not followed by a U wave or
if distinct from the following U wave. If a U wave followed
by the T wave, T wave offset was measured as the nadir
between the T and U waves. In case of a flat T wave or TU
merge without nadir, the end of the T wave could not be
determined and the lead was excluded from measure-
ments. The QT intervals were measured in all 12 leads
and corrected for heart rate (QTc) by Bazett’s formula, to-
gether with a sex-specific method described by Rautaharju
and Zhang [25] according to AHA/ACCF/HRS guidelines
[26]. QT dispersion and QTc dispersion were calculated
as the difference between the maximum and minimum
QT interval and QTc interval, respectively, among the 12
leads. Tpeak-Tend was defined as the interval from the
peak of positive T wave and the end of the T wave and
was measured in lead V5.Statistical analysis
Numeric variables are expressed as means ± SD. Differ-
ences between two groups were tested by Student’s t-
test. Relationships between parameters were examined
by the use of simple linear regression analyses. Multiple
regression analyses were performed to determine the re-
lationships between clinical parameters, QT dispersion
and Tpeak-Tend. Changes in clinical and electrocardio-
graphic variables and medication during follow-up pe-
riods within the type 2 diabetes group (36 patients) were
compared by the paired t-test and Fisher’s exact test, re-
spectively. Statistical analyses were carried out using
JMP (version11 SAS Institute, Cary, NC, USA). To cal-
culate statistical power for differences in QT dispersion
and Tpeak-Tend, we used “Power and Sample Size Cal-
culation version 3.0.43, 2011”. All statistical tests weretwo-tailed and differences were considered to be statisti-
cally significant if p was less than 0.05.
Results
Baseline characteristics
Clinical characteristics in the type 2 diabetes and control
groups are shown in Table 1. Body mass index (BMI)
was larger and systolic blood pressure (BP) was higher
in the type 2 diabetes group than in the control group.
However, BP was relatively well-controlled by medica-
tions in most of the diabetic patients (124.8 ± 16.8/74.2 ±
9.4 mmHg), with only 8 patients (18%) showing systolic
BP ≥140 mmHg. Duration of diabetes was 12.5 ± 12.0 years
(median, 6.5 years) and 72% of the patients had one or
more complications: 14 with retinopathy, 18 with ne-
phropathy (stage 2 or 3), 7 with autonomic neuropathy,
and 9 with coronary artery disease. Autonomic neur-
opathy in the seven patients was diagnosed from postural
hypotension (n = 2), reduced coefficient of variance of RR
intervals (CVRR) on ECG (n = 4) or diabetic neurogenic
bladder (n = 1). Patients with coronary artery disease had
been medically treated with or without prior coronary
interventions, and none of them showed myocardial ische-
mia in exercise ECG tests or stress myocardial scintig-
raphy at the time of study enrollment. Glycemic control
was poor (fasting plasma glucose: 170.3 ± 49.5 mg/dl,
HbA1c: 10.0 ± 1.6%) at the time of admission. As expected
in poorly controlled diabetes, triglyceride level was signifi-
cantly higher and high-density lipoprotein cholesterol
(HDL-C) level was significantly lower in type 2 diabetic
patients than in controls. Low-density lipoprotein choles-
terol (LDL-C) levels were comparable in the two groups,
most likely as a result of cholesterol-lowering therapy in
36% of the patients, mainly with a statin.
Electrocardiographic measurements
Heart rate was significantly higher in type 2 diabetic pa-
tients than in controls (Table 1). The sum of S wave
depth in lead V1 and R wave height in lead V5 (V1S +
V5R, an index for left ventricular mass, with ≥3.5 mV
being defined as left ventricular hypertrophy by the
Sokolow-Lyon voltage criterion) tended to be larger in
diabetic patients, although only two subjects in each
group met the ECG criterion for left ventricular hyper-
trophy. Mean QTc interval (413.6 ± 18.5 vs. 408.3 ±
22.7 ms) was not significantly longer in type 2 diabetic
patients than in controls, and a similar trend was ob-
served when QT was adjusted using the method of
Rautaharju and Zhang (407.4 ± 15.6 vs. 406.9 ± 21.0 ms).
In contrast, QT dispersion (41.8 ± 15.4 vs. 28.7 ± 7.7 ms)
and QTc dispersion (45.9 ± 16.3 vs. 28.8 ± 7.3 ms) were
significantly increased in type 2 diabetic patients com-
pared with those in controls. Increased QTc dispersion
in type 2 diabetic patients was also detected by use of




(n = 44) (n = 44)
Clinical variables
Age (years) 60.6 ± 13.8 58.4 ± 11.4 0.353
Male 24 (54.5%) 22 (50.0%) 0.674
BMI (kg/m2) 26.7 ± 4.4 22.6 ± 2.8 <0.001
SBP (mmHg) 124.8 ± 16.8 118.3 ± 13.4 0.048
DBP (mmHg) 74.2 ± 9.4 71.6 ± 9.7 0.204
Smoking 24 (54.5%) 20 (45.5%) 0.400
Duration of DM (years) 12.5 ± 12.0 N/A
Retinopathy 14 (31.8%) N/A
Nephropathy 18 (40.9%) N/A
Autonomic neuropathy 7 (15.9%) N/A
CAD 9 (20.5%) N/A
Laboratory variables
FPG (mg/dl) 170.3 ± 49.5 89.7 ± 8.0 <0.001
HbA1c (%) 10.0 ± 1.6 5.6 ± 0.3 <0.001
Triglyceride (mg/dl) 228.1 ± 246.0 88.2 ± 38.9 <0.001
HDL-C (mg/dl) 44.5 ± 12.4 54.8 ± 10.2 <0.001
LDL-C (mg/dl) 115.9 ± 40.0 129.4 ± 27.4 0.0069
Creatinine (mg/dl) 0.66 ± 0.22 0.64 ± 0.14 0.597
Uric acid (mg/dl) 5.0 ± 1.4 5.1 ± 1.4 0.596
Potassium (mEq/l) 4.1 ± 0.4 4.3 ± 0.1 0.074
Medications
ACE-I/ARB 16 (36.4%) N/A
CCB 13 (29.5%) N/A
β blocker 5 (11.4%) N/A
Other antihypertensive drugs 8 (18.2%) N/A
Sulphonylurea 19 (43.2%) N/A
α-glucosidase inhibitor 19 (43.2%) N/A
Biguanide 16 (36.4%) N/A
DPP-4 inhibitor 14 (31.8%) N/A
Insulin 8 (18.2%) N/A
Other antidiabetic drugs 6 (13.6%) N/A
Statin 14 (31.8%) N/A
Fibrate 2 (4.5%) N/A
Electrocardiographic variables
Heart rate (bpm) 74.2 ± 15.5 61.0 ± 8.6 <0.001
V1S + V5R (mV) 2.37 ± 0.58 2.14 ± 0.68 0.093
QTc mean (ms) 413.6 ± 18.5 408.3 ± 22.7 0.229
Table 1 Baseline characteristics (Continued)
QT dispersion (ms) 41.8 ± 15.4 28.7 ± 7.7 <0.001
QTc dispersion (ms) 45.9 ± 16.3 28.8 ± 7.3 <0.001
Tpeak-Tend in V5 (ms) 83.6 ± 13.6 71.3 ± 10.3 <0.001
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood
pressure, CAD = coronary artery disease, FPG = fasting plasma glucose, HbA1c =
glycated hemoglobin, HDL-C = high-density lipoprotein cholesterol, LDL-C =
low-density lipoprotein cholesterol, ACE-I = angiotensin-converting enzyme
inhibitor, ARB = angiotensin II receptor blocker, CCB = calcium channel blocker,
DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor. QTc = corrected QT (by Bazett’s
formula), N/A= not applicable. Values are means ± SD or absolute numbers
(frequency percentages).
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vs. 35.1 ± 12.8 ms, p < 0.01). Tpeak-Tend (83.6 ± 13.6 vs.
71.3 ± 10.3 ms) and Tpeak-Tend/QT ratio (0.220 ± 0.028
vs. 0.175 ± 0.022) were significantly longer in the diabetic
group than in the control group, indicating increased
heterogeneity of ventricular repolarization in type 2
diabetes.
Multiple regression analysis indicated that HbA1c and
systolic BP were independent determinants of both QT
dispersion and Tpeak-Tend, indices of heterogeneity in
ventricular repolarization (Table 2). On the other hand,
neither QT dispersion nor Tpeak-Tend in type 2 dia-
betes was correlated with duration of diabetes (Figure 2).Effect of glycemic control on heterogeneity in ventricular
repolarization
After discharge from our hospital, 31 patients were
followed at the out-patient clinic of our hospital and en-
rolled in the follow-up study. The remaining 13 patients
were followed at affiliated clinics. We confirmed that all
of the 13 patients have been free from cardiovascular
events, but ECG and laboratory data of 8 patients were
not available for the present analyses. Therefore, we ana-
lyzed changes in electrocardiographic variables and clin-
ical data for 36 patients at baseline and during follow-up
after treatment of diabetes (Table 3, Figure 1). The pro-
portions of patients on each medication did not signifi-
cantly change during a mean follow-up period of 787.0 ±
300.8 days (median, 754 days), except for increased fre-
quency in use of dipeptidyl peptidase (DPP)-4 inhibitors
at the end of the follow-up period. HbA1c level was sig-
nificantly reduced from 10.0 ± 1.7 to 7.3 ± 1.6%, although
BMI and BP were unchanged during the follow-up period.
Triglyceride and LDL-C were significantly reduced after
treatments, probably due to low calorie/fat intake as diet
therapy, improvement of glycemic control, increased use
of statins (50.0 vs 33.3%) and/or their combination. Serum
creatinine level significantly increased from 0.67 ± 0.23 to
0.99 ± 0.85 mg/dl, and this trend was still observed even
after exclusion of two patients who developed stage 5 ne-
phropathy (0.80 ± 0.28 mg/dl).
Table 2 Multiple regression analyses for electrical heterogeneity indices
QT dispersion Tpeak-Tend
B SE β t p B SE β t p
Age (years) 0.043 0.120 0.039 0.353 0.720 −0.001 0.110 −0.001 −0.008 0.990
Sex (male) −0.148 1.400 −0.011 −0.109 0.910 −1.520 1.300 −0.113 −1.180 0.240
BMI (kg/m2) −0.093 0.370 −0.028 −0.248 0.810 −0.295 0.350 −0.092 −0.838 0.400
SBP (mmHg) 0.233 0.095 0.261 2.450 0.016 0.188 0.090 0.216 2.100 0.039
HbA1c (%) 2.050 0.660 0.374 3.130 0.002 2.710 0.620 0.504 4.380 <0.001
Triglyceride (mg/dl) −0.009 0.008 −0.126 −1.140 0.260 −0.012 0.008 −0.166 −1.560 0.120
n = 88, R2 = 0.224, AIC = 706.0 n = 88, R2 = 0.281, AIC = 695.5
BMI = body mass index, SBP = systolic blood pressure, HbA1c = glycated hemoglobin.
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before and after glycemic control. Despite the consider-
able reduction in HbA1c after treatment of diabetes,
mean QTc interval, QT dispersion and Tpeak-Tend in
lead V5 did not significantly changed (Table 3). Further-
more, there was no significant correlation between
change in HbA1c, creatinine or LDL-C and change in
QT dispersion or Tpeak-Tend during the follow-up
period (Figure 3).Figure 2 Neither QT dispersion (A) nor Tpeak-Tend (B) was
correlated with duration of diabetes (log transformed).Discussion
The majority of previous studies have shown that QTc
interval was prolonged in diabetic patients compared to
that in non-diabetic controls [27,28]. In the present
study, however, QTc interval in type 2 diabetic patients
(413.6 ± 18.5 ms) was similar to that in control subjects
(408.3 ± 22.7 ms). Although Bazett’s formula has been
the most frequently used method to adjust QT intervals
for heart rate, it tends to underestimate or overestimate
the duration of repolarization when heart rate is rela-
tively slow or fast. Since heart rate was faster in diabetic
patients than in control subjects, we also corrected QT
intervals for heart rate using a method proposed by
Rautaharju and Zhang [25]. However, as was the case
with Bazett’s formula, the method of Rautaharju and
Zhang also did not yield a significant difference in QTc
interval between diabetic patients and controls (407.4 ±
15.6 vs. 406.9 ± 21.0 ms). In contrast, QT dispersion and
QTc dispersion, indices for global dispersion, and
Tpeak-Tend, an index for transmural dispersion, were
significantly increased in type 2 diabetic patients com-
pared to those in controls. It has been shown that QT
dispersion and/or QTc dispersion are better prognostic
markers than QTc interval in diabetes to predict cardio-
vascular mortality [16,17]. The present results suggest
that increases in QT dispersion, QTc dispersion and
Tpeak-Tend precede the QTc prolongation, thereby be-
ing useful for detection of repolarization abnormality at
an earlier stage. Alternatively, QT dispersion, QTc dis-
persion and Tpeak-Tend may be more sensitive than
QTc interval for detecting even slight abnormalities in
repolarization.
Electrical repolarization abnormalities have been shown
to be associated with increased systolic BP, left ventricular
hypertrophy, presence of coronary artery disease, auto-
nomic dysfunction or microalbuminuria in patients with
diabetes [24,27,29,30]. Since these complications are in-
creased when the duration of diabetes is prolonged, we
presumed that repolarization abnormality would be re-
lated to disease duration. However, neither QT dispersion
nor Tpeak-Tend was correlated with duration of diabetes




Duration of treatments (days) - 787.0 ± 300.8
BMI (kg/m2) 26.5 ± 4.7 26.0 ± 4.8 0.239
SBP (mmHg) 126.6 ± 18.0 127.5 ± 14.9 0.564
DBP (mmHg) 75.1 ± 9.9 71.0 ± 9.4 0.051
Laboratory variables
HbA1c (%) 10.0 ± 1.7 7.3 ± 1.6 <0.001
Triglyceride (mg/dl) 184.8 ± 120.2 148.5 ± 81.9 0.043
HDL-C (mg/dl) 44.4 ± 11.8 46.9 ± 13.1 0.289
LDL-C (mg/dl) 116.0 ± 41.5 97.3 ± 28.8 0.020
Creatinine (mg/dl) 0.67 ± 0.23 0.99 ± 0.85 0.011
Uric acid (mg/dl) 4.9 ± 1.2 5.1 ± 1.4 0.504
Potassium (mEq/l) 4.2 ± 0.4 4.1 ± 0.5 0.734
Medications
ACE-I/ARB 13 (36.1%) 18 (50.0%) 0.341
CCB 11 (30.6%) 12 (33.3%) 1.000
β blocker 5 (13.9%) 6 (16.7%) 1.000
Other antihypertensive drugs 6 (16.7%) 8 (22.2%) 0.767
Sulphonylurea 17 (47.2%) 13 (36.1%) 0.474
α-glucosidase inhibitor 16 (44.4%) 11 (30.6%) 0.330
Biguanide 14 (38.9%) 18 (50.0%) 0.477
DPP-4 inhibitor 10 (27.8%) 27 (75.0%) <0.001
Insulin 7 (19.4%) 10 (27.8%) 0.580
Other antidiabetic drugs 4 (11.1%) 2 (5.6%) 0.674
Statin 12 (33.3%) 18 (50.0%) 0.232
Fibrate 2 (5.6%) 1 (2.8%) 1.000
Electrocardiographic variables
Heart rate (bpm) 73.6 ± 14.4 70.6 ± 11.0 0.156
V1S + V5R (mV) 2.42 ± 0.60 2.58 ± 0.74 0.097
QTc mean (ms) 414.1 ± 19.3 414.8 ± 23.0 0.843
QT dispersion (ms) 41.4 ± 16.6 45.8 ± 15.0 0.165
QTc dispersion (ms) 45.1 ± 16.8 46.8 ± 14.4 0.564
Tpeak-Tend in V5 (ms) 85.0 ± 12.9 83.6 ± 10.6 0.563
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood
pressure, CAD = coronary artery disease, FPG = fasting plasma glucose, HbA1c =
glycated hemoglobin, HDL-C = high-density lipoprotein cholesterol, LDL-C =
low-density lipoprotein cholesterol, ACE-I = angiotensin-converting enzyme
inhibitor, ARB = angiotensin II receptor blocker, CCB = calcium channel blocker,
DPP-4 inhibitor = dipeptidyl peptidase-4 inhibitor, QTc = corrected QT (by Bazett’s
formula), Values are means ± SD or absolute numbers (frequency percentages).
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Festa et al. [27] showing that QT interval was already pro-
longed in newly diagnosed diabetes. We also examined
the relationship between presence of coronary artery dis-
ease or autonomic dysfunction and repolarization abnor-
malities. However, the values of both QT dispersion andTpeak-Tend were similar in diabetic patients regardless of
the presence or absence of coronary artery disease or
autonomic dysfunction (data not shown). There is a possi-
bility that the small number of patients with these compli-
cations made it difficult to detect the difference, but our
results suggest that the presence of coronary artery disease
and autonomic dysfunction are not major predictors of re-
polarization abnormalities.
We found that HbA1c was an independent and strong
explanatory variable for increased QT dispersion and
Tpeak-Tend in this study (Table 2). This result is in ac-
cordance with results of studies showing that poor gly-
cemic control was associated with prolonged QT
interval [31,32]. However, except for the association with
HbA1c and BP, relationships between diabetes-related
changes in clinical parameters and repolarization abnor-
mality have not been clarified in previous studies
[27,28,31,32]. Therefore, we tested the hypothesis that
glycemic control could improve repolarization abnor-
mality in diabetic patients. While HbA1c level signifi-
cantly decreased from 10.0 ± 1.7 to 7.3 ± 1.6% during the
follow-up period, none of the repolarization indices im-
proved after treatment of diabetes. Furthermore, there
was no significant correlation between change in HbA1c
and change in QT dispersion or Tpeak-Tend during the
follow-up period (Figure 3). To the best of our know-
ledge, this is the first report that glycemic control failed
to improve repolarization abnormalities.
Several classes of anti-diabetic drugs were used for gly-
cemic control in the present study subjects. Previous
studies have shown that biguanide, DPP-4 inhibitors and
sodium glucose cotransporter 2 inhibitors do not modify
ventricular repolarization [33-35]. On the other hand,
sulfonylurea inhibits ATP-sensitive K+ channels not only
in pancreatic β cells but also on the sarcolemma of car-
diomyocytes, resulting in prolongation of the QT inter-
val [33]. Although approximately 40% of the patients
were treated with sulfonylurea in the present study,
those patients were taking glimepiride, which has less ef-
fect than glibenclamide on cardiac ATP-sensitive K+
channels [36]. Furthermore, the number of patients
treated with sulfonylurea was not increased during the
follow-up. Therefore, it is unlikely that the failure of gly-
cemic control to improve repolarization abnormalities is
attributable to the medicines used for glycemic control
in the present study. Recent large clinical trials have
shown that intensive glycemic control failed to reduce
cardiovascular and all-cause mortality [6-10] during 2 to
5 years of treatment. A benefit of glycemic control in re-
ducing the risk of cardiovascular disease was observed
only when the follow-up period was long (10–20 years)
in even newly diagnosed diabetic patients [37]. There is
the possibility that the follow-up period (787.0 ±
300.8 days) in the present study was too short to show
Figure 3 There were no correlations between changes in QT dispersion (A) and Tpeak-Tend (B) and change in HbA1c level. Change in
QT dispersion was also not correlated with change in LDL-C level (C) or creatinine level (D).
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cemic control. Nevertheless, the present results are con-
sistent with the results of recent clinical trials showing
that intensive glycemic control failed to reduce cardio-
vascular mortality [6-10].
In contrast to the failure of glycemic control to im-
prove repolarization abnormalities in the present study,
protective effects of BP and lipid control have been re-
ported in patients with diabetes and/or hypertension
[28,38,39]. Treatment with an angiotensin-converting
enzyme inhibitor and a calcium channel blocker signifi-
cantly decreased QT dispersion in patients with hyper-
tension, and this effect was correlated with the degree of
left ventricular hypertrophy [38]. In hypertensive pa-
tients with diabetes, treatment with aliskiren, a direct
renin inhibitor, reduced QT dispersion at 12 weeks after
treatment [39]. These results may reflect the outcomes
of clinical trials showing that interventions for hyperten-
sion and dyslipidemia have improved cardiovascular and
all-cause mortality in patients with diabetes [40,41].
Festa et al. [27] showed that systolic BP and LV mass,
but not glucose level, were determinants of the QT
interval in diabetic patients. Cox et al. [15] reported that
systolic BP was higher in a prolonged QTc group
(152.8 mmHg) than that in a normal QTc group
(139.6 mmHg) of type 2 diabetic patients, though HbA1c
levels in the two groups were similar (8.2% vs. 7.7%). Inthe present study, multiple regression analysis revealed
that systolic BP was an independent predictor of QT dis-
persion and Tpeak-Tend (Table 2), and an ECG marker
of left ventricular mass (V1S + V5R) tended to be higher
in diabetic patients. These results suggested that high BP
and consequent increase in ventricular mass are stronger
determinants than HbA1c for increased heterogeneity of
ventricular repolarization in diabetic patients. In the
present study, BP in diabetic patients was well-controlled
by medications both at baseline and during the follow-up
periods (Table 3), indicating that significant improvement
of glycemic control does not attenuate repolarization ab-
normality by diabetes even under good BP control.
Treatment with a statin has been shown to improve
repolarization heterogeneity in patients with diabetes in
a study by Tekin et al. [28]. They reported that treat-
ment of diabetic patients with simvastatin for 12 weeks
decreased LDL-C from 142 mg/dl to 80 mg/dl and re-
duced QT and QTc dispersions by 24% and 27%, re-
spectively. Whether the LDL-C-reducing property of
simvastatin or its pleiotropic effect contributed to the
improvement of repolarization heterogeneity remains
unclear. In the present study, QT dispersion was not re-
duced during the follow-up period, although LDL-C was
reduced by 17% in association with an increase in the
proportion of patients on statins (Table 3). A plausible
explanation for the discrepancy between the present
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well-controlled LDL-C level at baseline in the present
study: LDL-C level was within the recommendation
range (LDL-C <120 mg/dl in diabetic patients, Japan
Atherosclerosis Society Guidelines for Prevention of
Atherosclerotic Cardiovascular Diseases 2012) at base-
line and change in LDL-C level during the follow-up
period was within normal ranges.
It has been shown that severe hypoglycemia is associ-
ated with increased cardiovascular mortality, and fatal
arrhythmias caused by abnormal ventricular repolariza-
tion during hypoglycemia could be one of the mecha-
nisms [42,43]. Significant prolongation of QT interval
during hypoglycemia has also been observed in previous
studies [42-45]. In this study, there was no episode of se-
vere hypoglycemia in patients during hospitalization or
the follow-up, but mild hypoglycemia and hypoglycemia
unawareness could not be totally excluded in retrospect-
ive analysis of medical records. Hence, to examine the
possibility that mild hypoglycemic episodes, if any, had
an impact on ventricular repolarization in the diabetic
patients, we divided the diabetic patients into a sub-
group treated with sulfonylurea and/or insulin and a
subgroup treated with other agents. Although sulfonyl-
urea and insulin are known to increase the risk of
hypoglycemia compared with other agents, QT disper-
sion and Tpeak-Tend were similar in the subgroups of
patients treated with or without sulfonylurea and/or in-
sulin (39.5 ± 15.0 vs. 43.8 ± 15.8 ms for QT dispersion
and 84.6 ± 13.0 vs. 82.8 ± 14.2 ms for Tpeak-Tend). We
also analyzed blood glucose levels at the outpatient clinic
when follow-up ECG was taken in the 36 diabetic pa-
tients. Glucose levels ranged from 80 to 280 mg/dl
(mean: 156.3 ± 44.3 mg/dl), and thus none of follow-up
ECGs were recorded at the time of hypoglycemia. These
findings argue against the possibility that improvement
of ventricular repolarization by glycemic control was
masked by mild ~modest hypoglycemic episodes in the
present study.
There are several limitations in this study. First, the
number of patients was small and the follow-up period
of diabetic treatment was relatively short. Statistical
power for detection of differences in QT dispersion and
Tpeak-Tend between type 2 diabetes and control groups
(N = 44 each) was 0.998 and 0.987, respectively, suggest-
ing that it was sufficient power (>0.80) in baseline com-
parison in this study. On the other hand, statistical
power for longitudinal changes in the indices of ven-
tricular repolarization is not large due to the relatively
small number of patients (i.e., 0.332 for QT dispersion
and 0.094 for Tpeak-Tend), and thus the possibility of a
type 2 error cannot be excluded. Second, no major ad-
verse cardiac event or death occurred during the follow-
up period. Therefore, the observed impact of increasedQT dispersion and Tpeak-Tend on the clinical outcome
could not be confirmed.
Conclusions
Increased heterogeneity of ventricular repolarization in
diabetic patients was not normalized by significant gly-
cemic control within a few years. The results are consist-
ent with the results of recent clinical trials showing that
intensive glycemic control failed to reduce cardiovascu-
lar mortality. Whether intensive glycemic control for
more than a few years ultimately reverses the repolariza-
tion heterogeneity remains to be further investigated.
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